The Efficacy and Tolerability of Acarbose in Healthy Individuals

AgelessRx

Status and phase: Completed; Phase 4

Conditions: Side Effect; Tolerance; Glucose Response

Treatments: Drug: Acarbose Tablets 50mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT05542849

ALRx006

Details and patient eligibility

About

A Prospective Trial for Acarbose in Healthy Individuals Assessing Safety and Efficacy in Reducing Glucose Spikes After Carbohydrate Consumption.

Enrollment: 15 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Age 18-85
2. Any sex
3. Any ethnicity
4. Interest in taking Acarbose off-label
5. Approved by the AgelessRx Medical team to take Acarbose
6. Willing and technically able to use and operate a CGM
7. Own a CGM-compatible phone
8. Relatively good health with only well-managed chronic diseases (hypertension, coronary artery disease, type II diabetes, etc.) clinically stable
9. Adequate cognitive function to be able to give informed consent

Exclusion criteria

1. Diabetes of any type
2. Taking metformin or any other glucose lowering medication
3. Any uncontrolled endocrine disorder (thyroid, pancreatic, adrenal, etc...)
4. Active malignancy of any kind
5. Clinically relevant renal or kidney disease or dysfunction
6. History of eating disorder
7. Taking any medication, or has any medical condition that might interfere with the action of acarbose of the CGM sensor

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

15 participants in 2 patient groups

Arm A

Experimental group

Treatment:

Drug: Acarbose Tablets 50mg

Arm B

Experimental group

Treatment:

Drug: Acarbose Tablets 50mg